Regeneration Technologies, Inc. (RTIX)

mdriver78 (< 20) Submitted: 6/09/08 4:04 AM : Start Price: $10.12 RTIX Score: -11.54

The revenues, earnings and margins are growing and in the hightlights from the most recent quarter reveals a great story for a future of long term growth:





- Successful completion of merger with Tutogen to form RTI Biologics


- Reported gross margins of 47 percent before purchase accounting adjustments related to merger with Tutogen – a year-over-year improvement of 1000 basis points and a sequential gain of 300 basis points from the fourth quarter 2007


- Achieved record sports medicine revenues, increasing by 71 percent over the first quarter 2007


- Delivered initial shipment of Puros® allograft bone paste to Zimmer Inc.


- Launched fresh-stored osteochondral allograft line at the American Academy of Orthopaedic Surgeons (AAOS)





As a result of the Tutogen merger, revenues in 2008 include the new lines of business for dental and surgical specialties, as well as additional international distribution originating from the German facility.





Further, the Co announced the successful implantation of its first fresh-stored osteochondral (OC) allograft in Arkansas in Mid June 08.





The female patient, 40, with a history of persistent knee pain due to articular cartilage damage, underwent a microfracture procedure approximately one year ago, but the lesion persisted. The fresh-stored OC allograft allowed the surgeon to resurface the defect with mature hyaline cartilage, while providing the patient with a smooth articulating surface.





This Co is in the early stages of profitability and the successful merging of newly acquired business shows a sound management team with a good eye for value added strategies going forward.

Report this Post Replies: 0 | Reply